4//SEC Filing
Parschauer Karah Herdman 4
Accession 0000950170-25-030639
CIK 0001515673other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 1:58 PM ET
Size
10.3 KB
Accession
0000950170-25-030639
Insider Transaction Report
Form 4
Parschauer Karah Herdman
EVP and Chief Legal Officer
Transactions
- Sale
Common Stock
2025-02-27$42.75/sh−760$32,490→ 54,991 total - Award
Stock Option (Right to Buy)
2025-03-01+26,074→ 26,074 totalExercise: $42.92Exp: 2035-03-01→ Common Stock (26,074 underlying) - Sale
Common Stock
2025-02-27$42.93/sh−2,230$95,734→ 55,751 total - Award
Common Stock
2025-03-01+14,494→ 69,690 total
Footnotes (4)
- [F1]Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- [F2]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F3]Includes 205 shares acquired on October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan
- [F4]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001677455
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 1:58 PM ET
- Size
- 10.3 KB